Harry Therianos

INTEGRIS Pharma is a fast-growing Greek pharmaceutical company. Founded in 2008 as a CNS generics pharma, the company successfully relaunched its business model in 2018, with a clear mission to cover the unmet therapeutic needs of patients with rare, debilitating and life-threatening diseases in Greece and Cyprus, through innovative therapeutics. Consistently serving this new strategic and therapeutic focus, INTEGRIS Pharma is actively seeking for innovative medicines throughout the world and is committed to ensure direct access for all patients, in the countries the company operates. Within the last 5 years, INTEGRIS Pharma has entered into 12 new partnerships with leading, global biopharmaceutical companies and has built an extensive and diverse product portfolio for more than 16 diseases. Its portfolio includes orphan drugs for rare and ultra-rare diseases, innovative biopharmaceuticals complemented with hybrid and generic products in the fields of Oncology and Hematology as well as first-in-class therapeutic products of advanced technology for wound healing. Acknowledging the great impact of these diseases to the lives of patients, their families and caregivers, the company is committed to offering a holistic, integrated disease management approach, extending from product management that meets the highest quality and safety standards, to patient-centric initiatives that aim to address the needs of patients across their journey with the disease.